Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has at least a 2-year history of seasonal allergic rhinitis with typical symptoms~* Male or female who is unlikely to conceive: a surgically sterilized female, female who has reached natural menopause, or is of reproductive potential and agrees to either remain abstinent or use (or have her partner use) 2 acceptable methods of birth control from study start through 14 days after the last dose of study drug.~Exclusion Criteria:~* Has a lower respiratory tract infection or has a nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.) requiring treatment~* Has a coexisting infection or systemic mycosis for which there are no effective antibiotics~* Has asthma that is under treatment and/or uncontrolled~* Has nasal septum ulcers, nasal surgery, or nasal trauma which have not healed~* Has vasomotor rhinitis or eosinophilic rhinitis~* Has a history of hypersensitivity to antihistamines or ingredients of study drug~* Has had treatment with corticosteroids (oral, injectable, suppository, depot drugs \[injectable\]) or immunological drugs within 28 days prior to Visit 2~* Is currently receiving treatment with another investigational drug or has received an investigational drug within prior 3 months~* Has started specific desensitization therapy (allergen immunotherapy) or nonspecific allassotherapy (Histaglobin, vaccine therapy, etc.) or who has received such therapies within prior 3 months~* Has received coagulation or resection using laser therapy etc. for treatment for nasal symptoms~* Will receive nasal nebulizer therapy and/or thermotherapy during study period~* Has severe hepatic, renal, cardiac, hematological disease, or other serious coexisting diseases and whose general condition is poor~* Has a history of malignancy or clinically important hematological disorder, except for adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix~* Has a history of severe drug allergy (e.g. anaphylactoid reaction)~* Is pregnant or lactating or may be pregnant~* Is planning a remote trip for more than 1 day during the Symptom Confirmation Period or for more than 2 days during the Treatment Period.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desloratadine (Type: EXPERIMENTAL): After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded desloratadine (one 5 mg tablet) orally (PO) once daily (QD) in the morning for 2 weeks during the Treatment Period.
- Placebo (Type: PLACEBO_COMPARATOR): After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded placebo (one tablet) PO QD in the morning for 2 weeks during the Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).